1. Home
  2. EGY vs CABA Comparison

EGY vs CABA Comparison

Compare EGY & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VAALCO Energy Inc.

EGY

VAALCO Energy Inc.

HOLD

Current Price

$4.99

Market Cap

569.3M

Sector

Energy

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.11

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EGY
CABA
Founded
1985
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
569.3M
495.7M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
EGY
CABA
Price
$4.99
$3.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$7.30
$14.50
AVG Volume (30 Days)
1.4M
5.2M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
3.75%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
$359,272,000.00
N/A
Revenue This Year
$8.78
N/A
Revenue Next Year
$29.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.36
$1.26
52 Week High
$6.72
$4.23

Technical Indicators

Market Signals
Indicator
EGY
CABA
Relative Strength Index (RSI) 34.49 46.57
Support Level $4.55 $2.74
Resistance Level $5.69 $3.34
Average True Range (ATR) 0.20 0.22
MACD -0.04 0.01
Stochastic Oscillator 21.24 52.46

Price Performance

Historical Comparison
EGY
CABA

About EGY VAALCO Energy Inc.

VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: